Because Dr. Downar's research indicates that it's the number of sessions not the number of pulses that matters, and subsequent research is validated that 600 is not inferior to 1200 or 1800.
No disagreement here, but it's gonna require clinical trial sites that have that patient population which means OB/GYN participating in those clinical trials.
So you give them speed and they feel less depressed. Wot a surprise! How do you target the sucker, the clinical and competitive advantage that Magnus Medical makes such a big deal about with SAINT? Ah, the article reveals ONE-D uses "non-personalized, scalp-based targeting." Hardly any targeting at all compared to SAINT's fMRI, endless image data crunching, and neurosurgery software. Think that's all unnecessary, at least with the right drugs added? Can we have a little compare and contrast here and widen the focus beyond the latest bright, shiny object?
Takes more articles and research to get there. What we know thus far is that circuits matter and neuro plasticity matters. What is the best modality for each person is unclear...but all these options are better then small molecule meds for most
In the 37-page version of the article -- just too hard to get back on the screen -- the authors and developers reveal their attitude toward SAINT: suggesting a possible joint venture with Magnus in the future. I guess they think targeting might matter, despite their initial results without it.
Hopefully the clinical trials will pan out and we will have something this effective with little pill and time (suffering) burden. Portable is the icing on the cake!
When? Where? And how much?!
https://www.fermatahealth.com/ Request a consultation.
Fascinating. Any idea why the trial used 600 pulse sessions rather than 1200 or 1800 pulse sessions?
Because Dr. Downar's research indicates that it's the number of sessions not the number of pulses that matters, and subsequent research is validated that 600 is not inferior to 1200 or 1800.
OB/GYN here and advocating for future trials to include perinatal depression. Zuranolone is hard to access and almost always denied due to cost.
No disagreement here, but it's gonna require clinical trial sites that have that patient population which means OB/GYN participating in those clinical trials.
So you give them speed and they feel less depressed. Wot a surprise! How do you target the sucker, the clinical and competitive advantage that Magnus Medical makes such a big deal about with SAINT? Ah, the article reveals ONE-D uses "non-personalized, scalp-based targeting." Hardly any targeting at all compared to SAINT's fMRI, endless image data crunching, and neurosurgery software. Think that's all unnecessary, at least with the right drugs added? Can we have a little compare and contrast here and widen the focus beyond the latest bright, shiny object?
Takes more articles and research to get there. What we know thus far is that circuits matter and neuro plasticity matters. What is the best modality for each person is unclear...but all these options are better then small molecule meds for most
In the 37-page version of the article -- just too hard to get back on the screen -- the authors and developers reveal their attitude toward SAINT: suggesting a possible joint venture with Magnus in the future. I guess they think targeting might matter, despite their initial results without it.
It's a smalll universe of docs on the cutting edge, and we all know each other ;)
https://www.researchsquare.com/article/rs-5679327/v1
Linked in the article
I'm more than thrilled to be a part of this endeavor!!
Hopefully the clinical trials will pan out and we will have something this effective with little pill and time (suffering) burden. Portable is the icing on the cake!
Encouraged!... what's there to help cut or modify cravings for substance.. some thing new, shiny but effective as well?